Ginkgo biloba ? opportunities and risks

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16370%2F18%3A43876915" target="_blank" >RIV/62157124:16370/18:43876915 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Ginkgo biloba ? opportunities and risks
Original language description
In recent years, the standardized EGb 761 extract has been one of the most commonly clinically tested and most frequently prescribedphytopharmaceuticals in Europe, being registered as a medication in 72 countries. There is a multitude of preparations inthe market, ranging from registered medications with a precisely defined composition to products of untraceable manufacturerswith virtually unknown composition. Medications with EGb 761 are primarily intended to treat mild cognitive disorder, mild dementiaof the Alzheimer type, vascular dementias, and mixed dementias. Clinical trials show that the use of standardized Ginkgo biloba extract is safe and the occurrence of adverse effects is rare. Adulteration of GB products through the post-extraction addition of cheaper (e.g. Fagopyrum esculentum or Sophora japonica derived) flavonoids is common. A study conducted in Germany in 2010 showed that most of the GB food supplements sold in Germany are likely to be falsified.
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)